Back to Search
Start Over
Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs:A systematic review and meta-analysis
- Source :
- Grebely, J, Tran, L, Degenhardt, L, Dowell-Day, A, Santo, T, Larney, S, Hickman, M, Vickerman, P, French, C, Butler, K, Gibbs, D, Valerio, H, Read, P, Dore, G J & Hajarizadeh, B 2021, ' Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs : A systematic review and meta-analysis ', Clinical Infectious Diseases, vol. 73, no. 1, ciaa612, pp. e107-e118 . https://doi.org/10.1093/cid/ciaa612
- Publication Year :
- 2021
-
Abstract
- Background People who inject drugs (PWID) experience barriers to accessing testing and treatment for hepatitis C virus (HCV) infection. Opioid agonist therapy (OAT) may provide an opportunity to improve access to HCV care. This systematic review assessed the association of OAT and HCV testing, treatment, and treatment outcomes among PWID. Methods Bibliographic databases and conference presentations were searched for studies that assessed the association between OAT and HCV testing, treatment, and treatment outcomes (direct-acting antiviral [DAA] therapy only) among PWID (in the past year). Meta-analysis was used to pool estimates. Results Of 9877 articles identified, 22 studies conducted in Australia, Europe, North America, and Thailand were eligible and included. Risk of bias was serious in 21 studies and moderate in 1 study. Current/recent OAT was associated with an increased odds of recent HCV antibody testing (4 studies; odds ratio (OR), 1.80; 95% confidence interval [CI], 1.36–2.39), HCV RNA testing among those who were HCV antibody–positive (2 studies; OR, 1.83; 95% CI, 1.27–2.62), and DAA treatment uptake among those who were HCV RNA–positive (7 studies; OR, 1.53; 95% CI, 1.07–2.20). There was insufficient evidence of an association between OAT and treatment completion (9 studies) or sustained virologic response following DAA therapy (9 studies). Conclusions OAT can increase linkage to HCV care, including uptake of HCV testing and treatment among PWID. This supports the scale-up of OAT as part of strategies to enhance HCV treatment to further HCV elimination efforts.
- Subjects :
- Microbiology (medical)
medicine.medical_specialty
Hepatitis C virus
Treatment outcome
medicine.disease_cause
Antiviral Agents
03 medical and health sciences
0302 clinical medicine
Opioid Agonist
Internal medicine
IDU
Medicine
Humans
030212 general & internal medicine
Substance Abuse, Intravenous
PWID
injecting drug use
therapy
business.industry
Australia
Hepatitis C
Odds ratio
Hepatitis C, Chronic
medicine.disease
Thailand
Hcv elimination
Confidence interval
Analgesics, Opioid
Europe
Infectious Diseases
Treatment Outcome
Pharmaceutical Preparations
Meta-analysis
North America
HCV
care cascade
030211 gastroenterology & hepatology
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Grebely, J, Tran, L, Degenhardt, L, Dowell-Day, A, Santo, T, Larney, S, Hickman, M, Vickerman, P, French, C, Butler, K, Gibbs, D, Valerio, H, Read, P, Dore, G J & Hajarizadeh, B 2021, ' Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs : A systematic review and meta-analysis ', Clinical Infectious Diseases, vol. 73, no. 1, ciaa612, pp. e107-e118 . https://doi.org/10.1093/cid/ciaa612
- Accession number :
- edsair.doi.dedup.....9da47a1584ca7c60b590aaf02743b96c